Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 11/20 | 0.38 |
| ▸ | WNT1 | P04628 | 9/20 | 0.38 |
| ▸ | OGT | O15294 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | KDM5C | P41229 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.35 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16408119 | 0.80 | APP (0.41) | GSK3BDYRK1AWNT1OGTIDH1 | |
| SCHEMBL26354513 | 0.74 | PTGS2 (0.38) | GSK3BDYRK1AWNT1KDM4EKDM4A | |
| SCHEMBL9143504 | 0.73 | KDR (0.50) | ALDH1A1KDM4EKDM5C | |
| SCHEMBL28367077 | 0.72 | GSK3B (0.36) | GSK3BDYRK1AWNT1DPP4IDH1 | |
| SCHEMBL26098876 | 0.72 | PTGS2 (0.49) | GSK3BALDH1A1KDM4E | |
| Ammonia Solution, Strong SCHEMBL28862432 | 0.72 | KDR (0.49) | ALDH1A1KDM4EKDM5C | |
| SCHEMBL14446422 | 0.72 | KDR (0.52) | OGTALDH1A1LMNA | |
| SCHEMBL5049519 | 0.72 | NPC1 (0.42) | GSK3BDYRK1AWNT1ALDH1A1KDM4E | |
| SCHEMBL2682667 | 0.72 | PTGS2 (0.49) | GSK3BDYRK1AWNT1ALDH1A1KDM4E | |
| SCHEMBL28298649 | 0.72 | HSD17B1 (0.50) | GSK3BDYRK1AWNT1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773129-B2 | Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-10-03 | — | — | US | disclosed |
| US-20200239512-A1 | METHODS OF PREVENTING OR TREATING ATHEROSCLEROSIS WITH INHIBITORS OF SPECIFIC ISOENZYMES OF HUMAN NEURAMINIDASE | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239512-A1 | METHODS OF PREVENTING OR TREATING ATHEROSCLEROSIS WITH INHIBITORS OF SPECIFIC ISOENZYMES OF HUMAN NEURAMINIDASE | NEU1, NEU3, NEU2 | GSK3B 2394/4885DYRK1A 3786/4885WNT1 2948/4885 |
| US-11773129-B2 | Methods of preventing or treating atherosclerosis with inhibitors of specific isoenzymes of human neuraminidase | NEU1, NEU3, NEU2 | GSK3B 2394/4885DYRK1A 3786/4885WNT1 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.